Overview
Analyst Coverage
Corporate Governance
Press Releases
Stock Information
SEC Filings
Annual Reports
Information Requests
Investor FAQs
Home

Press Releases

2010 | 2009 | 2008 | 2007 | 2006
DateTitle  
09/07/10Neuralstem Collaborator to Present Stroke Study Results at Stem Cell & Regenerative Medicine ConferenceDownload PDFPrinter Friendly Version
08/25/10Neuralstem Files FDA Application for First Chronic Spinal Cord Injury Stem Cell TrialDownload PDFPrinter Friendly Version
08/18/10Neuralstem Receives Confirmation of Patent Claims From United States Patent and Trademark OfficeDownload PDFPrinter Friendly Version
08/16/10Neuralstem Reports Second Quarter Financial Results and Provides Business & Clinical UpdateDownload PDFPrinter Friendly Version
06/30/10Neuralstem Completes $10 Million Registered Direct OfferingDownload PDFPrinter Friendly Version
06/25/10Neuralstem to Raise $10 Million in Registered Direct OfferingDownload PDFPrinter Friendly Version
06/04/10Neuralstem ALS Trial Principal Investigator To Speak At Brookings InstitutionDownload PDFPrinter Friendly Version
05/24/10Neuralstem Updates Clinical Trial ProgressDownload PDFPrinter Friendly Version
05/17/10Neuralstem, Inc. Reports First Quarter Financial Results and Provides Business UpdateDownload PDFPrinter Friendly Version
05/10/10Neuralstem, Inc. to Present At World Stem Cells and Regenerative Medicine CongressDownload PDFPrinter Friendly Version
05/04/10CNN.com Health Features Neuralstem's Stem Cell TreatmentDownload PDFPrinter Friendly Version
04/30/10Neuralstem's ALS Stem Cell Treatment Featured on CNNDownload PDFPrinter Friendly Version
03/31/10Neuralstem Announces 2009 Financial Results, Provides UpdateDownload PDFPrinter Friendly Version
02/18/10Neuralstem Completes $5.25 Million FinancingDownload PDFPrinter Friendly Version
01/21/10Neuralstem Announces First Patient Treated in ALS Stem Cell TrialDownload PDFPrinter Friendly Version

 

 
 | Home | Our Technology | Transplantation | About Neuralstem | News | Intellectual Property | The Business | Contact Us | Investor Relations Home |